Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

September 18, 2024 updated by: Hanaa Mohammed Mohammed Sayed, Assiut University
The main goal of this study is to assess the role of Netrin 1, neogenin and ZEB1 in PAS-associated invasion

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

  • To evaluate the immunohistochemical expression of these proteins in PAS specimens in comparison with the control placental tissues.
  • To correlate their expression with the demographic parameters.
  • To assess the correlation between their expression in PAS specimens.

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assiut, Egypt
        • Hanaa Mohammed Mohammed Sayed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

30 PAS specimens and 30 placental specimens from matched control.

Description

inclusion criteria

  • PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS

exclusion criteria

  • patients with fundal and middle anterior or posterior placenta,
  • pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
  • uterine scar pregnancies were excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
group A
30 placental specimens of PAS
Other: no intervention applied
no intervention applied
group B
30 placental specimens of heaithy women with normal pregnancy
Other: no intervention applied
no intervention applied

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
impact of netrin-1 in the pathophysiology of placenta accreta spectrum
Time Frame: baseline
  1. Evaluation of the immunohistochemical expression of netrin 1 in PAS specimens in comparison with the control placental tissues.
  2. Evaluation of the immunohistochemical expression of neogenin in PAS specimens in comparison with the control placental tissues
  3. Evaluation of the immunohistochemical expression of ZEB1 in PAS specimens in comparison with the control placental tissues.
  4. Correlate their immunohistochemical expression with the demographic parameters and assess the correlation between their expression in PAS specimens.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

January 1, 2023

Study Completion (Actual)

July 1, 2023

Study Registration Dates

First Submitted

November 9, 2020

First Submitted That Met QC Criteria

November 9, 2020

First Posted (Actual)

November 13, 2020

Study Record Updates

Last Update Posted (Actual)

September 20, 2024

Last Update Submitted That Met QC Criteria

September 18, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • netrin-1 in placenta accreta

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pathophysiology of Placenta Accreta

Clinical Trials on no intervention applied

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe